Andrew Casey

President & CEO

BIOTECanada

Andrew Casey became President and CEO of BIOTECanada in August, 2012.  In his role as President & CEO of BIOTECanada Andrew is responsible for the strategic operations of the Association representing Canada’s biotechnology sector.  As the head of BIOTECanada, he is the lead spokesperson for Canada’s biotechnology industry communicating on the industry’s behalf with government, regulators, international bodies, media and the Canadian public.

In his capacity as head of BIOTECanada Andrew also serves as:

  • Director, Board of Directors, BIOTECanada
  • Chair, International Council of Biotechnology Associations (ICBA)
  • Director, Board of Directors, Institute for Research in Immunology and Cancer, Commercialization of Research (IRICoR)
  • Director, Board of Directors, Arthritis Alliance of Canada (AAC)

Prior to joining BIOTECanada, Andrew served from 2004-2012 as Vice President, Public Affairs and International Trade with the Forest Products Association of Canada (FPAC). From 1993-2004 he was the Assistant Vice-President, Government Relations with the Canadian Life and Health Insurance Association. Between 1989 and 1993 Andrew worked on Parliament Hill as a political advisor in the office of the Federal Ministry of Finance.

Andrew Casey is a native of Montreal, Quebec.  After attending Loyola High School (Montreal) and St. Lawrence CEGEP (Quebec City) he graduated from Carleton University (Ottawa) with degree in Political Science.


All Sessions by Andrew Casey

Printer Friendly See Full Agenda

Agenda: Day 1 Oct 5, 2020

Agenda: Day 2 Oct 6, 2020

3:15 pm

3:15 pm

Panel Discussion: CANADIAN HEALTH & LIFE SCIENCES SECTOR

Canadian Talent — Combating the Health & Life Science “Brain Drain”

Of the 20 leading and emerging fintech hubs globally, Toronto ranked #8, Vancouver #12, Montreal #14 and Calgary #16. Unpack why the same can’t be said for Canada’s health and life sciences sector, and outline what can be done to change that. Take back strategies to galvanize your senior management (and MP) to build a resilient industry by:

  • Using the economic drivers of biotech and fintech as prime examples of successful strategy execution
  • Leveraging learning from key players
  • Incorporating government departmental mandates to strengthen the case for the benefit of all